McKesson Corporation (MCK) is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The optimism led by a solid fourth-quarter fiscal 2024 performance and improving demand for healthcare are expected to contribute further. However, stiff competition and weaker generic pharmaceutical pricing trends persist.Over the past year, this Zacks Rank #3 (Hold) stock has rallied 41.4%.The renowned health care services and information technology company has a market capitalization of ...